Dual Extended-Release Pregabalin Formulation for Stable Plasma Levels
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dosing regimens of pregabalin for conditions like neuropathic pain and epilepsy result in significant compliance issues and clinical side effects due to fluctuating plasma concentrations, making it challenging to develop a once-daily dosage form due to its unique absorption characteristics in the gastrointestinal tract.
Innovation Solution
Development of a dual extended-release pharmaceutical composition comprising a first component for short-term release (4-6 hours) and a second component for long-term release (24 hours), using polymers like hydroxypropyl cellulose and ethyl cellulose to control the release of pregabalin, allowing for a once-daily administration with reduced side effects and improved pharmacokinetics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immediate release formulations are used, then the drug is well absorbed in the small intestine and proximal colon, but plasma concentrations fluctuate sharply leading to compliance issues and side effects
Solution Approach 1:
The dosage form is divided into two distinct components: an immediate release component and an extended release component. Each component serves a specific function - the immediate release component provides rapid absorption in the small intestine and proximal colon, while the extended release component maintains therapeutic levels over 24 hours, thereby reducing plasma concentration fluctuations and associated side effects
Solution Approach 2:
The invention changes the release rate parameter of pregabalin from rapid (immediate release) to controlled (extended release) by using specific polymers such as hydroxypropyl cellulose and ethyl cellulose. This parameter change allows the drug to be released over an extended period, maintaining stable plasma concentrations and reducing the harmful effects of sharp fluctuations
2Reliability
If 2-3 daily doses are administered, then therapeutic effect is achieved, but compliance issues arise due to frequent dosing requirements
Solution Approach 1:
The extended release component is designed to release pregabalin continuously over 24 hours, providing uninterrupted therapeutic action. This continuous release pattern eliminates the need for multiple daily doses, improving patient compliance while maintaining therapeutic effectiveness throughout the dosing interval
3Ease of operation
If once-daily formulation is developed, then compliance improves and side effects reduce, but development is challenged by poor absorption in the distal colon
Solution Approach 1:
The invention applies different release characteristics to different components of the dosage form. The immediate release component is optimized for absorption in the small intestine and proximal colon where absorption is efficient, while the extended release component compensates for poor absorption in the distal colon by providing sustained release over time, ensuring adequate therapeutic levels are maintained throughout the GI tract
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dual extended-release formulation provides sustained therapeutic exposure to pregabalin, reducing side effects and improving compliance by maintaining lower Cmax values and minimizing fluctuations in plasma concentrations, thus offering a more effective treatment for conditions such as diabetic peripheral neuropathy, postherpetic neuralgia, epilepsy, and fibromyalgia.
Implementation Method 1
using polymers like hydroxypropyl cellulose and ethyl cellulose to control the release of pregabalin
Implementation Method 2
the composition comprises a first component that provides release of the pregabalin active ingredient over a time period of about 4 to about 6 hours, and a second component that provides release of the pregabalin active ingredient over a time period of about 24 hours
Data Source
AI summary
The present invention relates to extended-release pharmaceutical compositions comprising pregabalin or a salt thereof, which are adapted to release the pregabalin active ingredient according to a dual release profile. The formulations comprise two components, the first (fast ER) providing extended-release of the active ingredient in a short controlled manner lasting from about 4 to about 6 hours, and the second (slow ER or maintenance) providing extended release of the active ingredient over a period of 24 hours. The proportion of each component in the formulation may be adjusted to achieve the desired AUC and therapeutic effect following oral administration to a subject. The invention further relates to methods of using the pharmaceutical compositions for treating conditions and disorders which are responsive to pregabalin treatment, such as neuropathic pain associated with diabetic peripheral neuropathy (DPN), post herpetic neuralgia (PHN), epilepsy, seizures and fibromyalgia.